• Update II: Cancer Immunotherapy From Japan

    Posted July 14, 2013: by Bill Sardi

    Various skeptics challenged my online report of a study published in the journal Anticancer Research that 345 patients with end-stage spreading (metastatic) cancer at a clinic in Japan had been successfully treated with immunotherapy.  That published report presented three cases as examples.  Skeptics claimed only 3 of the 345 treated patients were successfully treated.

    I have received confirmation directly from the Saisei Mirai Clinic in Kobe, Japan, that these patients were successfully treated and are in 1-2 year remission following treatment with injectable Gc-MAF (macrophage activating factor), intravenous vitamin C and oral vitamin D plus lipoic acid.  The clinic doctors report few if any side effects, improved quality of life, increased appetite in end-stage patients and prolonged survival. The e-mail received from Japan can be read below.

    From: Saisei Mirai Clinic

    Subject: Re: Inquiry: GcMAF

    Date: July 13, 2013 1:35:59 AM PDT

    To: Bill Sardi

    Dear Bill,

    Thank you for your email. I’m sorry about the late reply. I got your email from Dr Sakamoto. He asked me to reply to you. My name is Martin Mette. I’m working with the other researchers and doctors on second generation GcMAF. I’ll try to answer your questions.

    Can you tell me if there were any significant side effects?

    There are generally no significant side effects with second generation GcMAF therapy except occasionally mild swelling, mild pain, itching, and slight redness at the injection site which is seen occasionally in a similar way to other injections. Low grade fever or eczema has been observed in about 1 out of 100 patients using GcMAF, but these were short-term effects. We have used high doses of GcMAF for critically ill patients without any problems at all. In fact we see improved quality of life, increased survival and increase appetite in advanced stage patients.

    Were these consecutively treated patients? (few drop outs?)

    Patients are treated naturally in a clinical setting. There are no drop outs unless the patient cannot continue due to reasons other than GcMAF therapy. It’s important to bear in mind that most patients come to our clinic only after they have exhausted most conventional options for treatment and the cancer is progressing or recurring. So these are the most challenging to cure.

    Were patients successfully treated with non-solid tumors? (lymphoma, leukemia?)

    We don’t treat many non-solid tumors such as leukemia, but we are planning to treat these more in the near future. We have treated patients with lymphoma.

    Does your group intend to lecture on this discovery?

    We’d be happy to lecture on our experience with GcMAF, but currently we haven’t made any plans for lectures outside Japan.

    What kind of attention are you receiving in Japan regarding this discovery?

    We are seeing increased interest from doctors in Japan and more doctors are starting to allow patients to seek additional treatment with GcMAF at our clinic.

    Please let me know if you have any questions.

    Best regards,

    Martin Mette

Leave a Reply

You must be logged in to post a comment.